Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 8

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 8
---
 member and Executive Chairman of the NLS Board and each of Prof. Michel Revel, Mr. Eran Iohan, Ms. Liora Oren and Ms. Tammy Galili to serve as members of the NLS Board for a term lasting until the next annual ordinary shareholders’ meeting of NLS. 10.To approve the election of Mr. Olivier Samuel, Mr. Eran Iohan and Ms. Liora Oren as members of the Compensation, Nomination and Governance Committee for a term lasting until the next annual ordinary shareholders’ meeting. 11.To approve on an advisory basis the appointment of the new senior management of the Company, as follows: Mr. Ronen Twito (Executive Chairman and Chief Executive Officer), Prof. Michel Revel, MD, PhD (Chief Scientific Officer), Mr. Kfir Molakandov, PhD (Vice President Research and Development), Mr. Ariel Revel, MD (Director of Medical Affairs) and Dr. Eric Konofal, MD, Ph.D. (Head of DOXA program). 12.1. (i) to approve a new maximum aggregate amount of CHF 200,000(cash based compensation including all applicable social security contributions) for the fixed compensation of the Board of Directors, (ii) to approve the grant of equity or equity linked instruments with maximum aggregate amount of CHF 350,000(equity or equity linked instruments including all applicable social security contributions) for the compensation of Board of Directors, and (iii) to approve the participation in the purchase of a run -offinsurance policy for the members of the Board of Directors, to be effective at the time of the Merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for the current term of office until the next Ordinary Shareholders Meeting. 12.2. (i) to approve the new maximum aggregate amount of CHF 494,000(cash compensation including all applicable social security contributions) for the fixed compensation of the Company’s executive officers, (ii) to approve the new maximum aggregate amount of CHF 2,206,000(cash compensation including all applicable social security contributions) for the variable compensation of the Company’s executive officers, (iii) to approve the grant of equity or equity linked instruments with maximum aggregate amount of CHF 991,000(equity or equity linked instruments including all applicable social security contributions) for the Company’s executive officers, and (iv) to approve the participation in the purchase of